BlossomHill Therapeutics, Inc. develops precision medicines targeting oncology and autoimmune disorders by utilizing advanced drug design techniques and human intelligence. The company aims to create therapies that overcome the limitations of existing treatments, improving patient outcomes in these challenging medical areas.

Cephla develops open and scalable bespoke microscope systems, including the motorized Squid+ platform, designed for high-performance imaging applications. They offer integrated solutions for confocal imaging, spatial biology, and high-content screening, supporting automation readiness via SiLA2 drivers. The company provides free, open-source software to control both their hardware and third-party tools, accelerating scientific data collection and discovery.

Corsair Pharma is developing a transdermal patch that delivers an inactive prodrug of treprostinil to provide consistent blood levels for patients with pulmonary arterial hypertension (PAH). This approach eliminates the need for invasive intravenous or subcutaneous administration, reducing pain and improving treatment adherence.

This startup provides a bisulfite conversion kit that simplifies DNA methylation analysis for epigenomic studies. Their ready-to-use reagent streamlines the process, enabling researchers and clinicians to achieve faster results with enhanced efficiency.

HebeCell develops a patented ProtoNK™ manufacturing platform that produces allogeneic natural killer (NK) cells for the treatment of cancer and viral infections. This technology enables scalable production of potent NK cells, providing off-the-shelf therapeutic options for patients with incurable diseases.

IASO Biotherapeutics develops cell therapies targeting specific cancer types by utilizing engineered immune cells to enhance the body’s natural ability to fight tumors. The company aims to improve patient outcomes in oncology by providing more effective treatment options for resistant cancer forms.

Oncimmune provides ImmunoINSIGHTS™, a high‑throughput, bead‑based multiplex assay that profiles autoantibody repertoires against a library of over 9,000 human and multi‑species antigens using less than 50 µL of serum or plasma. The platform combines Luminex xMAP® technology, automated robotic workflows, and proprietary bioinformatics to generate reproducible biomarker signatures for patient stratification, target identification, and safety monitoring across oncology, autoimmune, infectious and metabolic disease programs.

Perceptive designs and manufactures a handheld intraoral scanner utilizing optical coherence tomography (OCT) technology to capture 3D volumetric data with over 90% accuracy for caries detection, eliminating the need for ionizing radiation. The company is also developing a dental robotics system aimed at completing restorative procedures in 15 minutes, significantly reducing the time and complexity of traditional methods.

Proteovant Therapeutics is a biotechnology company focused on protein degradation research to develop targeted therapies for diseases caused by protein misfolding and aggregation. Their approach aims to enhance the efficacy of treatments by selectively eliminating harmful proteins, addressing unmet medical needs in various therapeutic areas.

Reunion Neuroscience is developing RE104, a patented prodrug of 4-OH-DiPT that targets the serotonin 2A receptor to provide fast-acting, short-duration therapeutic effects for postpartum depression and other mental health disorders. The company aims to deliver effective treatment options for patients whose needs are unmet by current antidepressant therapies.

The startup develops therapeutics that target the protein palmitoylation and depalmitoylation pathways to modulate immune responses in autoimmune diseases and cancer immunotherapies. By focusing on novel protein acylation mechanisms, the company aims to enhance treatment efficacy for a range of immune-related disorders.

Smartlens, Inc. develops miLens, a non-invasive device that continuously monitors intraocular pressure (IOP) to provide real-time data for glaucoma management. Their THERmic technology delivers personalized microdose treatments based on the patient's diurnal IOP, addressing the challenge of inadequate monitoring and treatment of glaucoma patients.

Subtle Medical develops AI-powered software solutions, SubtleMR™ and SubtlePET™, that enhance image quality and reduce acquisition time for MRI and PET scans. This technology addresses the challenges of long wait times and suboptimal imaging, enabling healthcare providers to improve patient throughput and maintain diagnostic confidence.